Showing results (51-60 of 300) with videos related to
Sort By:
Pageof 30
Transplantation Reviews (Orlando, Fla.)|December 6, 2014
Monitoring T cell alloreactivityAnita Mehrotra, Jeremy Leventhal, Carolina Purroy, et al.Clinical Kidney Journal|May 11, 2026
Beyond traditional roles: vitamin D and erythropoietin as immune modulators in kidney diseasesLorenza Magagnoli, Sofia Bin, Paolo Cravedi, et al.BMJ Case Reports|August 27, 2014
Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximabMaddalena Marasà, Paolo Cravedi, Barbara Ruggiero, et al.International Journal of Molecular Sciences|January 1, 2020
Complement and Complement Targeting Therapies in Glomerular DiseasesSofia Andrighetto, Jeremy Leventhal, Gianluigi Zaza, et al.Seminars in Nephrology|October 29, 2013
Complement regulation of T-cell alloimmunityPaolo Cravedi, William van der Touw, Peter S HeegerTransplantation Reviews (Orlando, Fla.)|May 15, 2024
Recurrent complement-mediated Hemolytic uremic syndrome after kidney transplantationShota Obata, Frank Hullekes, Leonardo V Riella, et al.Fibrogenesis & Tissue Repair|May 6, 2010
The role of renin angiotensin system inhibition in kidney repairIrene M van der Meer, Paolo Cravedi, Giuseppe RemuzziInternational Scholarly Research Notices|July 21, 2016
The Impact of Histologic Variants on FSGS OutcomesKristin Meliambro, Monica Schwartzman, Paolo Cravedi, et al.Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathyPaolo Cravedi, Piero Ruggenenti, Maria Chiara Sghirlanzoni, et al.Transplantation Reviews (Orlando, Fla.)|March 6, 2025
Transition from preclinical to clinical application of CTLA4-Ig co-stimulation blockage in beta-cell replacement therapyQuentin Perrier, Johan Noble, Sandrine LablanchePageof 30